Published in Cancer on November 15, 2009
Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol (2011) 2.10
Chemoradiation in patients with unresectable extrahepatic and hilar cholangiocarcinoma or at high risk for disease recurrence after resection : Analysis of treatment efficacy and failure in patients receiving postoperative or primary chemoradiation. Strahlenther Onkol (2012) 0.96
Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma. Strahlenther Onkol (2010) 0.89
Parametric survival models for predicting the benefit of adjuvant chemoradiotherapy in gallbladder cancer. AMIA Annu Symp Proc (2010) 0.88
Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma. BMC Cancer (2013) 0.82
Surgery Alone Versus Surgery Followed by Chemotherapy and Radiotherapy in Resected Extrahepatic Bile Duct Cancer: Treatment Outcome Analysis of 336 Patients. Cancer Res Treat (2015) 0.81
Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology. Medicine (Baltimore) (2015) 0.81
Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma. Radiat Oncol (2014) 0.77
Survival outcomes and progonostic factors of extrahepatic cholangiocarcinoma patients following surgical resection: Adjuvant therapy is a favorable prognostic factor. Mol Clin Oncol (2014) 0.75
A long survivor with local relapse of hilar cholangiocarcinoma after R1 surgery treated with chemoradiotherapy: a case report and literature review. Surg Case Rep (2016) 0.75
Does radiotherapy still have a role in unresected biliary tract cancer? Cancer Med (2016) 0.75
Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma. World J Gastrointest Surg (2013) 0.75
Comparison of external beam radiation and brachytherapy to external beam radiation alone for unresectable extrahepatic cholangiocarcinoma. J Gastrointest Oncol (2016) 0.75
External radiotherapy and brachytherapy in the management of extrahepatic and intrahepatic cholangiocarcinoma: available evidence. Br J Radiol (2017) 0.75
Adjuvant therapy in biliary tract and gall bladder carcinomas: a review. J Gastrointest Oncol (2017) 0.75
Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg (1996) 5.42
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg (2007) 3.73
Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol (2008) 3.44
Local therapy and survival in breast cancer. N Engl J Med (2007) 3.33
Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst (2006) 3.17
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96
Hospital volume and late survival after cancer surgery. Ann Surg (2007) 2.93
Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg (1995) 2.28
Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys (2000) 2.21
Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg (1990) 2.21
Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics (1995) 2.19
A test of several parametic statistical models for estimating success rate in the treatment of carcinoma cervix uteri. Br J Cancer (1975) 2.06
Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg (2007) 1.87
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2008) 1.83
Surgical management of cholangiocarcinoma. Semin Liver Dis (2004) 1.75
Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann Surg (1994) 1.72
The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys (1996) 1.68
Improved survival in resected biliary malignancies. Surgery (2002) 1.67
Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg (2003) 1.62
Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg (1997) 1.44
Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys (2002) 1.44
Modeling survival in colon cancer: a methodological review. Mol Cancer (2007) 1.36
External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2006) 1.33
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys (2007) 1.31
Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol (2000) 1.15
Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2008) 1.10
Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepatogastroenterology (2004) 1.10
Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. J Gastrointest Surg (2004) 1.08
Cholangiocarcinoma: the impact of tumor location and treatment strategy on outcome. Am J Clin Oncol (2003) 1.07
Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model. Ann Surg Oncol (2000) 1.06
Positive microscopic margins alter outcome in lymph node-negative cholangiocarcinoma when resection is combined with adjuvant radiotherapy. Am J Clin Oncol (2005) 1.00
Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder. Dig Dis Sci (2005) 0.99
Daily ultrasound-based image-guided targeting for radiotherapy of upper abdominal malignancies. Int J Radiat Oncol Biol Phys (2004) 0.99
Diagnosis and management of cholangiocarcinomas: a comprehensive review. Hepatogastroenterology (2004) 0.98
The role of radiotherapy in the treatment of bile duct carcinoma. Int J Radiat Oncol Biol Phys (1990) 0.96
Definitive postoperative irradiation of bile duct carcinoma with charged particles and/or photons. Int J Radiat Oncol Biol Phys (1993) 0.94
Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment. BMC Cancer (2007) 0.93
Carcinoma of the extrahepatic biliary system--results of primary and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys (1987) 0.92
Radiotherapy as a component of multidisciplinary treatment of bile duct cancer: a surgeon's perspective. J Hepatobiliary Pancreat Surg (2001) 0.92
Cholangiocarcinoma: clinical significance of tumor location along the extrahepatic bile duct. Radiology (1995) 0.88
Definitive radiation therapy for extrahepatic bile duct carcinoma. Radiology (1995) 0.86
Alternative multivariate modelling for time to local recurrence for breast cancer patients receiving a lumpectomy alone. Surg Oncol (1997) 0.85
External beam and intraluminal radiotherapy for locally advanced bile duct cancer: role and tolerability. Radiother Oncol (1996) 0.82
Comparison of parametric and non-parametric survival methods using simulated clinical data. Stat Med (1997) 0.82
Carcinoma of the extrahepatic biliary tract: surgery and radiotherapy for curative and palliative intent. Radiat Oncol Investig (1998) 0.81
Diagnosis and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer Treat Res (2001) 0.80
Use of adjuvant radiotherapy at hospitals with and without on-site radiation services. Cancer (2007) 0.79
Unresectable hilar cholangiocarcinoma completely reduced by external radiation therapy. Hepatogastroenterology (2005) 0.77
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol (2009) 9.84
The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med (2003) 6.06
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA (2008) 4.61
The effectiveness of depression care management on diabetes-related outcomes in older patients. Ann Intern Med (2004) 4.00
Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology (2010) 3.98
An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys (2007) 3.87
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst (2012) 3.69
Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol (2008) 3.44
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology (2004) 3.30
Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology (2005) 3.24
Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology (2011) 3.24
Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol (2008) 3.21
Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst (2006) 3.17
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.90
Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol (2013) 2.89
Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol (2005) 2.85
Design and implementation of a comprehensive outpatient Results Manager. J Biomed Inform (2003) 2.69
Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev (2009) 2.50
Bibliometric analysis of radiation oncology departmental scholarly publication productivity at domestic residency training institutions. J Am Coll Radiol (2009) 2.33
Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer (2011) 2.23
Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study. Hepatology (2014) 2.14
Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood (2010) 2.12
Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol (2011) 2.10
International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev (2010) 2.07
Current status of diversity by race, Hispanic ethnicity, and sex in diagnostic radiology. Radiology (2013) 2.02
Melatonin: from basic research to cancer treatment clinics. J Clin Oncol (2002) 1.99
Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol (2005) 1.88
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol (2012) 1.84
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2008) 1.83
Association of meat and fat intake with liver disease and hepatocellular carcinoma in the NIH-AARP cohort. J Natl Cancer Inst (2010) 1.81
Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001. Gynecol Oncol (2008) 1.78
Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis (2012) 1.75
Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat Genet (2013) 1.74
Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomarkers Prev (2011) 1.68
Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology (2012) 1.68
US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol (2009) 1.65
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res (2009) 1.64
Conditional survival in head and neck squamous cell carcinoma: results from the SEER dataset 1973-1998. Cancer (2007) 1.63
Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol (2004) 1.61
International patterns and trends in testis cancer incidence. Int J Cancer (2005) 1.60
Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys (2006) 1.60
Locally advanced pancreatic cancer. J Clin Oncol (2005) 1.55
The in vivo gene expression signature of oxidative stress. Physiol Genomics (2008) 1.55
A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol (2011) 1.54
Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. Int J Cancer (2010) 1.53
Depression and comorbid illness in elderly primary care patients: impact on multiple domains of health status and well-being. Ann Fam Med (2004) 1.53
Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys (2004) 1.53
Excess polymorphisms in genes for membrane proteins in Plasmodium falciparum. Science (2002) 1.52
Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst (2005) 1.51
Radiation therapy in the postoperative management of esophageal cancer. J Gastrointest Oncol (2010) 1.48
Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes. Oncology (Williston Park) (2010) 1.48
Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol (2010) 1.47
Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer (2007) 1.46
Conditional survival in gastric cancer: a SEER database analysis. Gastric Cancer (2007) 1.44
Birth weight and risk of testicular cancer. Int J Cancer (2008) 1.43
Conditional Survival in Anal Carcinoma Using the National Population-Based Survey of Epidemiology and End Results Database (1988-2012). Dis Colon Rectum (2016) 1.40
Ethnic disparities in conditional survival of patients with non-small cell lung cancer. J Thorac Oncol (2007) 1.35
Assessing potentially inappropriate prescribing in the elderly Veterans Affairs population using the HEDIS 2006 quality measure. J Manag Care Pharm (2006) 1.35
Organizational interventions employing principles of complexity science have improved outcomes for patients with Type II diabetes. Implement Sci (2007) 1.34
Intraoperative radiation therapy. J Clin Oncol (2007) 1.31
Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting. Int J Radiat Oncol Biol Phys (2010) 1.30
Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev (2002) 1.29
Interpreting the international trends in testicular seminoma and nonseminoma incidence. Nat Clin Pract Urol (2006) 1.29
Intrauterine environments and breast cancer risk: meta-analysis and systematic review. Breast Cancer Res (2008) 1.27
Locally advanced duodenal gangliocytic paraganglioma treated with adjuvant radiation therapy: case report and review of the literature. World J Surg Oncol (2005) 1.27
Melatonin as a radioprotective agent: a review. Int J Radiat Oncol Biol Phys (2004) 1.25
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist (2010) 1.23
Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab (2010) 1.22
Relative lack of conditional survival improvement in young adults with cancer. Semin Oncol (2009) 1.21
Conditional Survival in Rectal Cancer: A SEER Database Analysis. Gastrointest Cancer Res (2007) 1.21
Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev (2004) 1.20
Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst (2007) 1.20
Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. Hum Mol Genet (2013) 1.19
A systematic review and meta-analysis of perinatal variables in relation to the risk of testicular cancer--experiences of the son. Int J Epidemiol (2010) 1.19
Gene conversion as a source of nucleotide diversity in Plasmodium falciparum. Mol Biol Evol (2003) 1.19
HLA-B alleles associate consistently with HIV heterosexual transmission, viral load, and progression to AIDS, but not susceptibility to infection. AIDS (2010) 1.17
Association of genetic variants in the calcium-sensing receptor with risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev (2004) 1.16
Trends in testicular germ cell tumours by ethnic group in the United States. Int J Androl (2007) 1.16
Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology (2014) 1.15
Thirty years of rectal cancer research: a brief history. Oncology (Williston Park) (2008) 1.15
Multiple management modalities in esophageal cancer: epidemiology, presentation and progression, work-up, and surgical approaches. Oncologist (2004) 1.15
A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys (2005) 1.14
Marijuana use and testicular germ cell tumors. Cancer (2010) 1.13
Colorectal cancer in Hispanics: a population at risk for earlier onset, advanced disease, and decreased survival. Am J Clin Oncol (2006) 1.13
Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys (2010) 1.12
Biliary tract cancer and stones in relation to chronic liver conditions: A population-based study in Shanghai, China. Int J Cancer (2007) 1.12
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist (2010) 1.11